Drug Profile
Research programme: anti-microbial therapeutics - Assembly Biosciences
Alternative Names: AB M102; AB M103; ABI-M101; ABM-101; Gemicel based therapeutics - Ventrus Biosciences; Gemicel based therapeutics -Assembly Biosciences; Microbiome therapeutics - Assembly BiosciencesLatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Assembly Biosciences
- Class Antibacterials; Bacteria; Hepatoprotectants; Irritable bowel syndrome therapies; Proteins; Small molecules; Viruses
- Mechanism of Action Bacterial toxin inhibitors; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Clostridium difficile infections; Irritable bowel syndrome; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA (PO)
- 28 Feb 2021 No recent reports of development identified for research development in Irritable-bowel-syndrome in USA (PO)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA (PO)